39°58′29″N 116°20′24″E / 39.9747°N 116.3401°E
Sinopharm | |||||||
Company type | state-owned enterprise | ||||||
Industry | |||||||
Founded | November 26, 1998 | ||||||
Headquarters | 20 Zhichun Road, Haidian District, Beijing , China | ||||||
Area served | China, exported worldwide | ||||||
Key people | Liu Jingzhen (Chairman & Chinese Communist Party Committee Secretary)[1][2] | ||||||
Products | |||||||
Revenue | CN¥247.110 billion (2014) | ||||||
CN¥8.758 billion (2014) | |||||||
CN¥2.705 billion (2014) | |||||||
Total assets | CN¥199.192 billion (2014) | ||||||
Total equity | CN¥31.944 billion (2014) | ||||||
Owner | Chinese central government (100%) | ||||||
Parent | SASAC of the State Council | ||||||
Subsidiaries |
| ||||||
Chinese name | |||||||
Simplified Chinese | 中国医药集团总公司 | ||||||
Traditional Chinese | 中國醫藥集團總公司 | ||||||
| |||||||
short Chinese name | |||||||
Simplified Chinese | 国药集团 | ||||||
Traditional Chinese | 國藥集團 | ||||||
| |||||||
Footnotes / references in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards[3] |
China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.),[4] Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai), and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).
China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.[5]
Sinopharm was ranked 109th in the 2021 Fortune Global 500 list.[6]
Sinopharm was founded as China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).[citation needed]
Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.[7]
Pfizer announced the signing of a cooperation pact with Sinopharm Group in April 2023, with plans to seep approval for 12 drugs in China through 2025.[8]
Main articles: Sinopharm BIBP COVID-19 vaccine, Sinopharm WIBP COVID-19 vaccine, and Sinopharm CNBG COVID-19 vaccine |
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[9] the Sinopharm COVID-19 vaccine,[10] or BIBP vaccine,[10][11][12] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[13] BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19.[14]
Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[15] In December 2020, the UAE previously announced interim results showing 86% efficacy.[16] While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[17]
BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,[18][19][20] Africa,[21][22][23] South America,[24][25][26] and Europe.[27][28][29] Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.[30] On 7 May 2021, the World Health Organization approved the vaccine for emergency use[31] and Sinopharm later signed purchase agreements for 170 million doses from COVAX.[32]
The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.[citation needed]